Site last updated:
December 2011
Cancer Services Forum currently has 2172 registered members
BOPA response to the government’s £50 million Interim Cancer Drug Fund - Part Two
Share
A number of groups in NHS England undertake a similar process: South West Peninsula Health Technology Commissioning Group, Yorkshire Cancer Network Gateway Group, and Yorkshire and the Humber Specialist Commissioning Group.
5.2.2 Prioritisation and clinical effectiveness review
A tool developed by the South East London Cancer Network (SELCN) is an established method of horizon scanning used to prioritise funding for cancer medicines that have yet to be appraised by NICE.14 It was used by all five cancer networks in London in the financial year 2009/10, and its use has been extended to include cancer networks on the south east coast of England and at Mount Vernon, Middlesex, for this current financial year.
The tool is used to review regimens that are either scheduled to receive NICE guidance, or are likely to be licensed for a new indication, by the end of the following financial year. For other regimens, a review can be performed at the specific request of an oncology consultant.
Each regimen is assessed by a ‘scoring panel’ of clinicians, pharmacists and medical directors from the cancer networks taking part, using information from NICE, the Scottish Medicines Consortium, LCNDG and the All Wales Medicines Strategy Group. If no information is available from these sources, primary data are reviewed.
The panel attribute scores to each regimen (see Box 2 on the next page). These are reviewed at a consensus seminar to which clinical representatives, commissioners, patients and carers are invited. If individuals do not agree with the score given to a particular regimen (e.g. because a new study has since been published) they are invited to produce evidence as to why a score should be changed.
Page 1 of 12
Discussion.